title: Role of oral teriflunomide in the management of multiple sclerosis.
abstract: The landscape of the treatment of relapsing-remitting multiple sclerosis is changing fast. Several oral treatments have shown benefit and generate much interest because of the convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have been approved in relapsing-remitting multiple sclerosis, while others have completed Phase III trials and are awaiting review for registration. Teriflunomide is a pyrimidine synthesis inhibitor with selective immunomodulatory and immunosuppressive properties that have shown consistent efficacy in clinical trials, and a good safety profile. This paper provides an overview of the mechanisms of action and efficacy and safety results from clinical trials with this drug. The role of teriflunomide in the treatment of relapsing-remitting multiple sclerosis is discussed.
authors: Academic Division of Clinical Neurology, University of Nottingham, Nottingham, UK ; Department of Neurology, Colentina Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
authors: Radu
authors: R
authors: Tanasescu
authors: Nikos
authors: N
authors: Evangelou
authors: Cris S
authors: CS
authors: Constantinescu
keywords: clinical trials; multiple sclerosis; oral drugs; teriflunomide
references: Results Probl Cell Differ. 2010;51:259-85
references: 20838962
references: Biochem Pharmacol. 1996 Aug 23;52(4):527-34
references: 8759024
references: Degener Neurol Neuromuscul Dis. 2012 Mar 10;2:15-28
references: 30890875
references: Br J Pharmacol. 1999 Aug;127(7):1589-96
references: 10455314
references: J Leukoc Biol. 2004 Nov;76(5):950-60
references: 15328336
references: Expert Rev Clin Pharmacol. 2012 May;5(3):245-56
references: 22697588
references: Neurology. 2011 Jul 26;77(4):355-63
references: 21775734
references: Rheumatology (Oxford). 2008 Feb;47(2):224-5
references: 18045807
references: Immunopharmacology. 2000 May;47(2-3):273-89
references: 10878294
references: Curr Opin Neurol. 2012 Feb;25 Suppl:S11-9
references: 22398660
references: N Engl J Med. 2012 Sep 20;367(12):1098-107
references: 22992073
references: Nat Rev Neurol. 2013 Jan;9(1):8-10
references: 23147843
references: Brain Res. 2001 Jan 19;889(1-2):331-8
references: 11166726
references: Arthritis Rheum. 2010 May;62(5):1494-503
references: 20131283
references: Drug Des Devel Ther. 2012;6:175-86
references: 22888218
references: Arthritis Res Ther. 2012 Jul 12;14(4):R163
references: 22784880
references: FEBS Lett. 1993 Nov 15;334(2):161-4
references: 8224241
references: Acta Neurol Scand. 2011 Aug;124(2):75-84
references: 20880295
references: Lancet. 2008 Oct 25;372(9648):1502-17
references: 18970977
references: Eur Cytokine Netw. 1998 Dec;9(4):663-8
references: 9889411
references: Lancet Neurol. 2011 Nov;10(11):1026-34
references: 22014437
references: Drug Metab Lett. 2007 Dec;1(4):299-305
references: 19356059
references: Mult Scler. 2012 Sep;18(9):1278-89
references: 22307384
references: Int MS J. 2008 Jun;15(2):62-8
references: 18782502
references: Ann Neurol. 2011 Feb;69(2):292-302
references: 21387374
references: N Engl J Med. 2010 Feb 4;362(5):402-15
references: 20089954
references: Mult Scler. 2012 Dec;18(12):1680-1
references: 23235776
references: Teratology. 2001 Feb;63(2):106-12
references: 11241434
references: Agents Actions. 1991 Jan;32(1-2):10-21
references: 2058454
references: Cell Immunol. 2000 Feb 1;199(2):73-80
references: 10698616
references: Mult Scler. 2012 Nov;18(11):1625-32
references: 22723573
references: Clin Pharmacokinet. 2002;41(6):421-30
references: 12074690
references: Drug Saf. 2009;32(12):1123-34
references: 19916579
references: N Engl J Med. 2010 Feb 4;362(5):416-26
references: 20089960
references: Arthritis Rheum. 2005 Sep;52(9):2730-9
references: 16142756
references: Neurology. 2012 Jun 5;78(23):1877-85
references: 22622860
references: Nat Rev Neurosci. 2012 Jun 20;13(7):507-14
references: 22714021
references: J Med Chem. 2013 Apr 25;56(8):3148-67
references: 23452331
references: J Immunol. 2002 Sep 15;169(6):3392-9
references: 12218161
references: Int MS J. 2009 Sep;16(3):90-7
references: 19878631
references: Int J Immunopharmacol. 1998 Sep;20(9):505-13
references: 9818794
references: J Neurol. 2009 Jan;256(1):89-103
references: 19169851
references: Mult Scler. 2012 Dec;18(12):1705-17
references: 22371220
references: Rheumatology (Oxford). 2009 Sep;48(9):1069-72
references: 19321513
references: J Biol Chem. 1995 May 26;270(21):12398-403
references: 7759480
references: J Immunol. 1998 Feb 15;160(4):1581-8
references: 9469413
references: Arch Neurol. 2011 Sep;68(9):1156-64
references: 21555606
references: Brain. 2001 Sep;124(Pt 9):1791-802
references: 11522581
references: N Engl J Med. 2011 Oct 6;365(14):1293-303
references: 21991951
references: N Engl J Med. 2012 Mar 15;366(11):1000-9
references: 22417253
references: Clin Exp Immunol. 2004 Sep;137(3):612-6
references: 15320915
references: N Engl J Med. 2012 Sep 20;367(12):1087-97
references: 22992072
references: Arch Neurol. 2008 Nov;65(11):1538-9
references: 19001176
references: N Engl J Med. 2010 Feb 4;362(5):387-401
references: 20089952
references: BMJ. 2002 Dec 7;325(7376):1333
references: 12468482
references: Clin Immunol. 2012 Jan;142(1):49-56
references: 21367665
references: Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882
references: 23235682
references: N Engl J Med. 2005 Aug 4;353(5):487-97
references: 16079372
references: Expert Opin Pharmacother. 2010 Jul;11(10):1777-81
references: 20408749
references: Neurology. 2006 Mar 28;66(6):894-900
references: 16567708
references: Clin Rheumatol. 2013 Feb;32(2):267-70
references: 23179005